Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
For full access to this article login to GEN Select now.
Safety Biomarkers Holy Grail of Toxicology
Firms Develop New Technologies, Big Pharma Collaborates, & the FDA Stresses Predictive Tests
- There is a great need to reduce the cost of developing new pharmaceuticals, now approaching $900 million per drug. About 75% of this cost is attributed to failed drugs. The FDA estimates that a 10% improvement in predicting clinical trial failures could reduce the average cost of drug development ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.